Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis
Research output: Contribution to journal › Journal article › Research › peer-review
Type 17 helper T cells have been suggested to play a pathological role in psoriasis. They secrete several proinflammatory cytokines, including interleukin-17A (also known as interleukin-17). We evaluated the safety and efficacy of ixekizumab (LY2439821), a humanized anti-interleukin-17 monoclonal antibody, for psoriasis treatment.
|Journal||New England Journal of Medicine|
|Number of pages||10|
|Publication status||Published - 2012|